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ABSTRACT
Background Comedication with conventional synthetic 
disease- modifying antirheumatic drugs (csDMARDs) during 
treatment with tumour necrosis factor inhibitors (TNFi) is 
extensively used in psoriatic arthritis (PsA), although the 
additive benefit remains unclear. We aimed to compare 
treatment outcomes in patients with PsA treated with TNFi 
and csDMARD comedication versus TNFi monotherapy.
Methods Patients with PsA from 13 European countries 
who initiated a first TNFi in 2006–2017 were included. 
Country- specific comparisons of 1 year TNFi retention were 
performed by csDMARD comedication status, together with 
HRs for TNFi discontinuation (comedication vs monotherapy), 
adjusted for age, sex, calendar year, disease duration and 
Disease Activity Score with 28 joints (DAS28). Adjusted ORs 
of clinical remission (based on DAS28) at 12 months were 
calculated. Between- country heterogeneity was assessed 
using random- effect meta- analyses, combined results were 
presented when heterogeneity was not significant. Secondary 
analyses stratified according to TNFi subtype (adalimumab/
infliximab/etanercept) and restricted to methotrexate as 
comedication were performed.
Results In total, 15 332 patients were included (62% 
comedication, 38% monotherapy). TNFi retention varied 
across countries, with significant heterogeneity precluding a 
combined estimate. Comedication was associated with better 
remission rates, pooled OR 1.25 (1.12–1.41). Methotrexate 
comedication was associated with improved remission for 
adalimumab (OR 1.45 (1.23–1.72)) and infliximab (OR 1.55 
(1.21–1.98)) and improved retention for infliximab. No effect 
of comedication was demonstrated for etanercept.
Conclusion This large observational study suggests 
that, as used in clinical practice, csDMARD and TNFi 
comedication are associated with improved remission 
rates, and specifically, comedication with methotrexate 
increases remission rates for both adalimumab and 
infliximab.
INTRODUCTION
Tumour necrosis factor inhibitors (TNFi) have 
become a cornerstone in the treatment of psoriatic 
Key messages
What is already known about this subject?
 ► Conventional synthetic disease- modifying 
antirheumatic drugs (csDMARDs) are often used 
in combination with tumour necrosis factor 
(TNF)- inhibitors in psoriatic arthritis, although 
the added benefit of such comedication, over 
TNF- inhibitor monotherapy, has been disputed.
What does this study add?
 ► Treatment retention of TNF- inhibitors varied 
significantly across countries, as did the 
utilisation of a concomitant csDMARD, and 
overall, there was no additional improvement 
in TNF- inhibitor retention when used together 
with a csDMARD.
 ► Comedication with methotrexate in patients 
treated with adalimumab or infliximab 
was associated with a 50% increase in the 
probability of achieving DiseaseActivity Score 
with 28 joints (DAS28) remission at 1 year, 
compared with TNF- inhibitor monotherapy.
 ► Comedication with csDMARDs in patients 
treated with etanercept provided no additional 
advantage over TNF- inhibitor monotherapy, in 
terms of either retention or DAS28 remission 
rates.
How might this impact on clinical practice or 
future developments?
 ► Our findings support the prevailing clinical 
strategy of combining monoclonal TNF- 
inhibitors with methotrexate in psoriatic 
arthritis.
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arthritis (PsA). Despite this, no international consensus has been 
reached regarding the optimal use of TNFi in PsA. Thus, the 
current American College of Rheumatology guidelines recom-
mend using TNFi as a first- line disease- modifying antirheumatic 
drug (DMARD), and, in patients previously failing a conven-
tional synthetic conventional synthetic DMARD (csDMARD), to 
switch to rather than to add a TNFi.1 In contrast, the European 
Alliance of Associations for Rheumatology (EULAR) recommen-
dations suggest using csDMARDs (methotrexate in particular) 
as the first- line DMARD and to then step up the treatment by 
adding, rather than switching to, a biological DMARD, such as 
a TNFi.2
The discrepancy in international guidelines stems from the 
limited and conflicting data comparing the different treatment 
strategies. While the effect of TNFi has been compellingly 
demonstrated in all domains of PsA,3 the effect of metho-
trexate is derived from expert opinion,2 one large randomised 
clinical trial (RCT) (which failed to show an effect of metho-
trexate),4 randomised trials not specifically designed to assess 
this effect5 6 and a few smaller randomised trails.7 8 The recent 
Study of Etanercept and Methotrexate in Subjects with Psori-
atic Arthritis (SEAM)- trial, comparing etanercept and metho-
trexate monotherapy with combination therapy, demonstrated 
a superior response for etanercept compared with methotrexate, 
but additionally, a good response to methotrexate monotherapy.9 
Importantly, no additional effect of combination therapy over 
etanercept monotherapy was demonstrated.9
Available data so far suggest that csDMARD (especially meth-
otrexate) and TNFi comedication therapy, compared with TNFi 
monotherapy, is not superior in terms of treatment response 
but may be beneficial for TNFi treatment retention.10–14 Never-
theless, a recent study from a collaboration across European 
treatment registries (the European Spondyloarthritis Research 
collaboration Network: EuroSpA) indicated that 60% of patients 
with PsA starting a TNFi used a concomitant csDMARD, and 
that 81% had previously used a csDMARD, suggesting extensive 
use of comedication in routine care.15 The 2019 EULAR recom-
mendations for the management of PsA stipulate that more data 
are needed on this subject.2
The objective of this observational study of patients with PsA 
in routine care was, therefore, to compare the 1- year TNFi treat-
ment retention and treatment response on joint manifestations, 
in patients starting a first TNFi as monotherapy compared with 
those starting a TNFi as combination therapy, that is, together 
with a csDMARD.
METHODS
This is an observational study based on prospectively collected 
data from 13 rheumatology registers in Europe, aggregated 
through the EuroSpA collaboration (as previously described15).
Data sources
Patients with PsA, aged 18 years or older, starting a first TNFi 
(adalimumab, certolizumab pegol, etanercept, golimumab, inflix-
imab) in 2006–2017 were identified from the following coun-
tries (registers): Czech Republic (ATTRA), Denmark (DANBIO), 
Finland (ROB- FIN), Iceland (ICEBIO), Italy (GISEA), Norway 
(NOR- DMARD), Portugal ( Reuma. pt), Romania (RRBR), 
Slovenia ( biorx. si), Spain (BIOBADASER), Sweden (ARTIS), 
Switzerland (SCQM) and Turkey (TURKBIO).
Time-point definitions and treatment groups
All participating registers recorded start dates (and stop dates in 
case of withdrawal) for the TNFi. The start date of the patients’ 
first TNFi was set as the baseline date, and the baseline visit was 
defined as the visit closest to the registered start date, within 
−100 to +30 days, giving priority to dates before the start date. 
The 3- month, 6- month and 12- month follow- up visits during 
treatment were defined as the date of visit closest to these time 
points, within the ranges: day 60–150, day 151–270 and day 
271–545, respectively, counting from the baseline date.
Registration of csDMARD use varied across the registers, with 
some recording start and stop dates, while others record treat-
ment status (use/no use) at registered visits. Thus, comedication 
use was either based on the start and stop dates (where available) 
for the csDMARD or on data on treatment status at registered 
visits.
The following two treatment exposure groups were defined: 
(1) The TNFi monotherapy group (=monotherapy group) 
including all patients starting a first TNFi without concurrent use 
of a csDMARD in a period from 100 days before to 30 days after 
baseline and (2) The TNFi and csDMARD comedication group 
(=comedication group) including all patients either starting a 
first TNFi together with a csDMARD (within 30 days) or starting 
a TNFi added to an already ongoing (and continued) csDMARD 
treatment. Changes in csDMARD treatment (withdrawal or 
Table 1 Baseline characteristics (mean (SD) or percentages) of 
patients with PsA starting their first TNFi as monotherapy or in 
combination with a csDMARD, pooled across all countries






N (%) 9440 (62%) 5892 (38%)
Age, years, mean (SD) 48.9 (12.1) 0% 49.0 (12.6) 0%
Sex (male), % 50% 0% 48% 0%
Disease duration, 
years mean (SD)
6.3 (7.1) 28% 6.2 (7.3) 32%
CRP, mg/L, mean (SD) 13.6 (21.3) 18% 9.1 (16.9) 25%
Tender joints 28, 
mean (SD)
6.2 (5.9) 21% 5.6 (6.1) 32%
Swollen joints 28, 
mean (SD)
3.9 (4.2) 21% 2.9 (4.0) 32%
VAS global health, 
mm, mean (SD)
59.2 (24.0) 21% 58.1 (25.6) 28%
VAS pain, mm, mean 
(SD)
57.4 (23.6) 30% 56.3 (25.7) 34%
DAPSA28, mean (SD) 28.8 (16.0) 38% 26.0 (16.9) 46%
DAS28- CRP, mean 
(SD)
4.2 (1.2) 29% 3.8 (1.3) 41%
Type of TNFi
  Adalimumab, % 32% – 33% –
  Certolizumab 
pegol, %
6% – 4% –
  Etanercept, % 30% – 40% –
  Golimumab, % 11% – 10% –
  Infliximab, % 20% – 13% –
Type of csDMARD used as co- medication
  Methotrexate, % 79% – – –
  Sulfasalazine, % 15% – – –
  Leflunomide, % 11% – – –
  Other*, % 6% – – –
*See the list of all csDMARDs in Methods section.
CRP, C reactive protein; csDMARD, conventional synthetic disease modifying anti- rheumatic 
drugs; DAPSA28, disease activity index for psoriatic arthritis with 28 joints; DAS28- CRP, 
disease activity score with 28 joints and CRP; PsA, psoriatic arthritis; TNFi, tumour necrosis 
factor inhibitors; VAS, visual analogue scale.
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switch to other csDMARD) during follow- up beyond 30 days 
from the baseline visit were not considered.
In the main analyses, the following csDMARDs were included: 
methotrexate, sulfasalazine, leflunomide, hydroxychloroquine, 
chloroquine, cyclosporine, azathioprine, mycophenolate and 
cyclophosphamide.
Patients were followed up from the baseline date until first 
of: TNFi stop date, last visit date +12 months, end of patient’s 
participation in the register or end of the study period (31 
December 2017).
Treatment retention
The 1- year treatment retention of the TNFi in the two treatment 
groups was compared through crude survival curves (Kaplan- 
Meier curves), and as HRs for TNFi discontinuation, with 
monotherapy as the reference.
Treatment response
Clinical remission at 12 months of treatment was defined 
following a hierarchical approach (online supplemental figure 
S1): for patients remaining on TNFi treatment beyond 12 
months, clinical remission was defined as 28- joint Disease 
Activity Score with 28 joints and CRP (DAS28- CRP) <2.6 at 
the 12- month visit.16 For patients with follow- up and treat-
ment longer than 12 months, but with DAS28 missing at the 
12- month visit, a DAS28 recorded at 6 months and up to 12 
months was carried forward. Patients discontinuing the TNFi 
before 12 months due to adverse events or lack of effect were 
considered not having achieved remission. Patients discontin-
uing the TNFi due to remission and not starting another TNFi 
before 12 months (27 patients) were considered as remaining in 
remission. Patients discontinuing the TNFi before 12 months for 
other reasons (eg, pregnancy) were considered as missing data. 
The reason for TNFi discontinuation was missing in only 11% 
of the patients with monotherapy and 3% with comedication.
Statistical analyses
Baseline characteristics of the patients are presented country 
specific and pooled for all countries, as means and SD (contin-
uous variables) or percentages (categorical variables).
Significant heterogeneity between countries was anticipated 
for both TNFi retention and treatment response. Therefore, all 
analyses were first performed individually per country, and only 
after disproving heterogeneity, combined results were presented 
(see below).
Country- specific HR of TNFi discontinuation was estimated 
using Cox regression adjusted for age, sex, calendar year, 
DAS28- CRP and disease duration at baseline.
Country- specific response rates of the two treatment groups were 
compared, based on the proportions and ORs of achieving clinical 
remission at 12 months and visualised through the average across 
individual patients’ delta-(∆)- DAS28- CRP (baseline DAS28- CRP 
minus 12 month’s DAS28- CRP). ORs of achieving remission at 12 
months (yes/no) were estimated using logistic regression adjusted 
for the same variables as mentioned above.
Overall results from both the Cox regression and the logistic 
regression analyses, per country, were combined using a random- 
effect meta- analysis. Statistical heterogeneity among countries 
was evaluated with the Cochran Q- test and the I2 statistic in 
order to assess the proportion of total variation that was due 
to between- country variation, based on the included cases with 
nonmissing data on the respective outcome.17
All data are reported as observed. No imputation of missing 
data was performed. In the regression models, baseline disease 
duration and DAS28 were categorised into quartiles to enable the 
use of a fifth category for missing data. The effectiveness analyses 
Figure 1 Country- specific 1 year treatment retention of co- medication and TNFi monotherapy (Kaplan- Meier retention curves), ordered by overall 
TNFi retention of the countries, from highest to lowest. Romania is not included in the figure due to <5 patients in the monotherapy group. TNFi, 
tumour necrosis factor inhibitors.
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were modelled only on patients with remission outcome data, and 
DAS28 at 6 months was carried forward if missing at 12 months.
Retention and effectiveness analyses were performed using R, 
V.3.6.3 (R Core Team (2020)). Meta- analyses were performed 
using Stata, V.14.2 (StataCorp, College Station, Texas, USA). 
Throughout all analyses, the level of statistical significance was 
set to 0.05. The proportional hazards assumption (for retention 
analyses) was assessed using the  cox. zph function of the R survival 
package.
Secondary analyses
All initial analyses were performed combining data for the 
different TNFi. Biosimilars were not distinguished from orig-
inators, and switches between originators and corresponding 
biosimilars were disregarded.
Due to the potential differential effect of csDMARD come-
dication according to the type of TNFi and comedication, 
secondary analyses were performed separately for the subgroup 
of patients treated with the most common TNFi (infliximab, 
adalimumab and etanercept: constituting 82% of the TNFi in 
the comedication group and 86% in the monotherapy group) 
and exploring the most common csDMARD, that is, metho-
trexate. In these subset analyses, country- specific comparisons 
were only performed if at least 30 patients were included in each 
of the treatment groups.
Patient and public involvement
Patients were not involved in the study.
RESULTS
In total, 15 332 patients starting a TNFi were included, of whom 
9440 (62%) were included in the comedication group (table 1) 
and 5892 (38%) in the TNFi monotherapy group.
Methotrexate was the most frequently used csDMARD (79%). 
There was a large variation in the proportion of monotherapy 
versus comedication across registers (monotherapy 1%–79%, 
figure 1 and online supplemental table S2). Overall, baseline 
characteristics were similar between the two treatment groups, 
with a slightly higher DAS28- CRP in the comedication group 
compared with the monotherapy group (4.2 vs 3.8, p value 
<0.001), a higher proportion of patients treated with infliximab 
in the comedication group and a higher proportion with etaner-
cept in the monotherapy group. The mean number of swollen 
and tender joints was also higher in the comedication group. 
Baseline characteristics per country are presented in online 
supplemental table S2 and the proportions of missing data in 
online supplemental table S3. Data from one register (Romania) 
were excluded from the stratified analyses due to a large imbal-
ance between the treatment groups (<5 patients included in the 
monotherapy group).
Treatment retention
The overall treatment retention of the TNFi differed between 
the countries, and the heterogeneity was statistically signif-
icant (I2=62.7%; p=0.002). It was, therefore, determined 
inappropriate to proceed with presentation of the combined 
result in a meta- analysis. The country- specific crude reten-
tion curves (figure 1) showed not only modest differences 
between the two treatment groups but also different direc-
tions of the effect of comedication versus TNFi monotherapy 
across countries. The retention curves of the individual coun-
tries by csDMARD use, demonstrated in figure 1, are ordered 
by the overall retention rates (from highest to lowest) of the 
TNFi in the registers. The overall TNFi retention regardless 
of comedication is shown in online supplemental figure S2.
The country- specific HR for discontinuation, adjusted 
for age, sex, calendar year, disease duration and DAS28, 
also showed different directions for the association between 
drug retention and use of comedication (figure 2). The HRs 
in eight of the countries were below 1 (range 0.52–0.95), 
indicating better retention for comedication, and above 1 in 
four countries (range 1.07–1.51) favouring monotherapy, but 
only in five of all 12 countries were these findings statistically 
Figure 2 Forest plot of country- specific hazard ratios for TNFi 
discontinuation at 12 months comparing TNFi and csDMARD co- 
medication with TNFi monotherapy, ordered by overall TNFi retention 
rate per country. Adjusted for baseline age, sex, calendar year, DAS28 
and disease duration. Combined results are not presented due to 
significant heterogeneity. Data from Romania are not presented due 
to <5 patients with monotherapy. csDMARDs,conventional synthetic 
disease- modifying anti- rheumatic drugs; DAS28, Disease Activity Score 
with 28 joints; TNFi, tumour necrosis factor inhibitors.
Figure 3 Forest- plot of country- specific ORs and overall OR for 
clinical remission at 12 months in TNFi and csDMARD co- medication 
compared with TNFi monotherapy. Adjusted for baseline age, sex, 
calendar year, DAS28 and disease duration. Data from Romania are 
not presented separately due to <5 patients with monotherapy. 
csDMARDs,conventional synthetic disease- modifying anti- rheumatic 
drugs; DAS28, Disease Activity Score with 28 joints; TNFi, tumour 
necrosis factor inhibitors.
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significant, figure 2. The assumption of proportional hazards 
was not rejected for all countries but Spain. Due to the clear 
direction of the results in Spain, this was not analysed further.
Treatment response
In contrast to the retention rates, the variation in response 
rates across the included countries was less pronounced, and 
there was no significant heterogeneity (I2=20.8%; p=0.239). 
The overall OR for achieving clinical remission at 12 months 
in the comedication group versus the monotherapy group 
was 1.25 (1.12–1.41) favouring comedication (figure 3). 
Excluding the two countries considered to be outliers in 
terms of the proportion of patients on comedication treat-
ment (21% and 99%) resulted in a very similar pooled OR 
of 1.27 (1.11–1.44) for remission. The ∆DAS28- CRP and the 
crude proportions achieving remission across the different 
registers (figure 4A,B) also suggested a tendency towards 
better outcomes in the co- medication groups. In total, 72% 
of the patients had complete outcome data and were included 
in the response analyses. Regarding patients in the csDMARD 
group who remained on the TNFi at 6 months, 82% also 
remained on csDMARD treatment.
Secondary analyses
The results of the secondary analyses, assessing the effect of 
methotrexate comedication separately for infliximab, adalim-
umab and etanercept, are presented in table 2.
Only three countries provided enough patients for all different 
strata of the secondary analyses. The number of patients included 
in the secondary analyses is presented in online supplemental 
table S4. In general, the differences in crude retention rates and 
the proportion reaching clinical remission were modest across 
the different TNFi, particularly between etanercept and adalim-
umab. The retention rate of etanercept was in line with that of the 
adalimumab comedication groups and somewhat higher than the 
infliximab groups (table 2). In four out of five contributing coun-
tries, the HR for infliximab discontinuation was in favour of meth-
otrexate comedication, but this was only statistically significant in 
two of the countries. For adalimumab, the HR of TNFi discontin-
uation was in favour of methotrexate comedication in 7 out of 10 
contributing countries (with statistically significant values below 
1 in two countries and above 1 in one country). For etanercept, 
the HR of discontinuation was in favour of methotrexate come-
dication in five countries and in favour of monotherapy in four 
contributing countries (all results were nonsignificant).
Figure 4 DAS28- CRP response at 12 months per country.(A) Delta DAS28- CRP between baseline and 12 months. (B) Proportions achieving 
remission at 12 months. Data from Romania are not presented due to <5 patients with monotherapy. csDMARDs,conventional synthetic disease- 
modifying ant- irheumatic drugs; DAS28, Disease Activity Score with 28 joints; TNFi, tumour necrosis factor inhibitors.
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The combined OR for remission indicated better outcomes 
for methotrexate comedication compared with monotherapy 
for infliximab (1.55 (1.21–1.98)) and adalimumab (1.45 (1.23–
1.72)), whereas no such association was observed for etanercept 
(1.12 (0.95–1.31)).
The distribution of DAS28 and the number of tender and swollen 
joints at baseline in the secondary analyses are presented in online 
supplemental figure S3. The comedication treatment groups were 
associated with higher baseline values of both DAS28 and number 
of swollen joints, indicating more active peripheral joint disease.
Table 2 Crude TNFi retention and adjusted HR for TNFi discontinuation (upper part of table), and crude proportion achieving remission and 
adjusted OR for clinical remission (lower part of table) for infliximab, adalimumab and etanercept, in co- medication with methotrexate compared 
with monotherapy
Infliximab Adalimumab Etanercept
One- year TNFi retention (%) and adjusted* HR for TNFi discontinuation (ref=monotherapy)
Czech republic co- med/mono NA 92%/79% 89%/89%
HR (95% CI) NA 0.36 (0.17 to 0.77) 1.06 (0.31 to 3.63)
Finland co- med/mono NA 87%/90% 95%/96%
HR (95% CI) NA 1.18 (0.41 to 3.35) 2.08 (0.31 to 13.94)
Italy co- med/mono 80%/87% 82%/88% 85%/89%
HR (95% CI) 1.45 (0.63 to 3.35) 1.63 (0.98 to 2.72) 1.45 (0.84 to 2.51)
Portugal co- med/mono NA 89%/97% 89%/84%
HR (95% CI) NA 7.39 (1.46 to 37.54) 0.60 (0.28 to 1.30)
Spain co- med/mono NA 82%/82% 77%/78%
HR (95% CI) NA 0.70 (0.26 to 1.90) 0.76 (0.30 to 1.90)
Slovenia co- med/mono NA 80%/67% NA
HR (95% CI) NA 0.90 (0.41 to 1.96) NA
Iceland co- med/mono 81%/78% NA NA
HR (95% CI) 0.81 (0.39 to 1.70) NA NA
Switzerland co- med/mono 77%/73% 79%/72% 80%/78%
HR (95% CI) 0.78 (0.39 to 1.58) 0.67 (0.45 to 1.00) 0.81 (0.49 to 1.35)
Sweden co- med/mono 71%/63% 78%/66% 76%/74%
HR (95% CI) 0.65 (0.50 to 0.85) 0.58 (0.47 to 0.72) 0.94 (0.77 to 1.14)
Norway co- med/mono NA 83%/68% 81%/70%
HR (95% CI) NA 0.59 (0.24 to 1.48) 0.59 (0.35 to 1.01)
Denmark co- med/mono 64%/45% 71%/70% 70%/72%
HR (95% CI) 0.56 (0.41 to 0.78) 0.93 (0.70 to 1.24) 1.12 (0.77 to 1.62)
Crude proportion (%) reaching remission at 12 months and adjusted* OR for clinical remission (ref=monotherapy)
Pooled co- med/mono 38%/32% 47%/38% 44%/42%
OR (95% CI) 1.55 (1.21 to 1.98) 1.45 (1.23 to 1.72) 1.12 (0.95 to 1.31)
Czech republic co- med/mono NA 57%/38% 68%/57%
OR (95% CI) NA 2.25 (1.23 to 4.20) 1.69 (0.66 to 4.33)
Finland co- med/mono NA NA NA
OR (95% CI) NA NA NA
Italy co- med/mono 29%/42% 43%/45% 46%/47%
OR (95% CI) 0.59 (0.12 to 2.58) 1.07 (0.55 to 2.07) 1.09 (0.59 to 2.02)
Portugal co- med/mono NA 54%/49% 51%/54%
OR (95% CI) NA 1.26 (0.49 to 3.27) 1.40 (0.64 to 3.15)
Spain co- med/mono NA NA NA
OR (95% CI) NA NA NA
Slovenia co- med/mono NA 42%/47% NA
OR (95% CI) NA 0.69 (0.28 to 1.68) NA
Iceland co- med/mono NA* NA NA
OR (95% CI) NA* NA NA
Switzerland co- med/mono NA 40%/33% 37%/21%
OR (95% CI) NA 1.68 (0.94 to 3.06) 2.94 (1.28 to 7.18)
Sweden co- med/mono 37%/27% 43%/33% 41%/38%
OR (95% CI) 1.73 (1.17 to 2.60) 1.59 (1.2 to 2.11) 1.03 (0.82 to 1.31)
Norway co- med/mono NA 54%/47% 49%/50%
OR (95% CI) NA 1.58 (0.54 to 4.66) 0.95 (0.52 to 1.74)
Denmark co- med/mono 34%/21% 45%/37% 42%/37%
OR (95% CI) 2.01 (1.13 to 3.72) 1.42 (0.99 to 2.03) 1.15 (0.72 to 1.85)
HR and OR are adjusted for age, sex, calendar year, disease duration and DAS28- CRP.
co- med/mono indicates the crude 1 year TNFi retention rate and the proportion in the co- medication/monotherapy groups reaching remission, respectively.
*NA=not available due to <30 patients in at least one of the exposure groups. Data from Romania and Turkey are not included in the table because they provided no strata in the analysis with ≥30 patients in both 
groups. Adjusted for baseline age, sex, calendar year, DAS28- CRP and disease duration.
CRP, C reactive protein; DAS28, Disease Activity Score with 28 joints; TNFi, tumour necrosis factor inhibitors.
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DISCUSSION
In this study of 15 332 patients with PsA initiating a first ever 
TNFi, based on data from 13 European countries, we found that 
csDMARD comedication was associated with a 25% improved 
rate of clinical remission at 12 months, compared with TNFi 
monotherapy. Regarding TNFi treatment retention, the results 
varied across the countries and no combined estimate could be 
assessed due to the significant heterogeneity. In the secondary 
analyses, significantly improved remission rates were observed 
for adalimumab and infliximab when used together with meth-
otrexate, and a trend towards better treatment retention for 
infliximab, while no advantage was found for combining etaner-
cept with methotrexate.
The initial RCTs for etanercept,18 infliximab19 and adalim-
umab20 did not indicate a difference in response between patients 
on monotherapy versus comedication with methotrexate, 
although these trials were generally restricted to patients with 
inadequate response to csDMARD. Similarly, the recent SEAM- 
trial9 and previous observational studies have in general not indi-
cated any additional treatment response for methotrexate when 
used in combination with a TNFi,10 although several studies 
have demonstrated improved TNFi retention.10–13 21 Based on 
these previous studies, our finding of an increased proportion 
achieving clinical remission in the csDMARD comedication 
group was unexpected.
Another recent register- based study (including data from three 
of the same registers, as the present study: Italy, Czech Republic 
and Switzerland) found no effect of comedication on treatment 
response.22 However, in that study, all TNFi were analysed 
together. By contrast, the results of our stratified secondary anal-
ysis suggest that clear differences between the TNFi can explain 
some of this discrepancy and that combining the drug- specific 
effects may have diluted the overall effect observed in that study. 
In line with previous studies, we found a trend for better TNFi 
treatment retention for infliximab, when used together with 
methotrexate, but not for etanercept, which corroborates the 
results from the SEAM trial.9 Further and similar to the SEAM 
trial, we found no additive effect on treatment response of meth-
otrexate when added to etanercept.9 Our findings of a 55% and 
45% higher odds for reaching remission at 12 months in the 
methotrexate comedication groups of infliximab and adalim-
umab, respectively, are novel findings. In particular, for adalim-
umab, the validity of these results is supported by the fact that all 
except one of the countries, included in that analysis, presented 
ORs in the same direction.
This study has some limitations. First, in contrast to the rela-
tively uniform results for the response rates, the pronounced 
intercountry differences in TNFi retention suggests that factors 
other than biological/pharmaceutical may have an influence 
on observed retention rates. Since the understanding of how 
such factors (eg, availability of drugs, prescription regulations 
and insurance policies) may influence the retention rates is 
incomplete, it was deemed beyond the scope of this paper to 
explore this further. However, these findings suggest that treat-
ment retention should be analysed in a way that accounts for 
such factors, and that pooling of retention data across coun-
tries should be performed with caution. Furthermore, use of 
csDMARD comedication in TNFi- treated patients varied from 
21% to 99% across the registers, suggesting large differences in 
treatment strategies in the participating countries. However, we 
do not believe that this biases the results, since excluding the 
outliers barley changed the pooled response outcome, and since 
there were no clear correlations between the proportions treated 
with comedication, and the direction and magnitude of remis-
sion and retention rates.
Second, use of 28- joint counts to define remission in PsA is 
inferior to the recommended 66/68- joint counts. However, this 
should not introduce a bias across the exposure groups, partic-
ularly not with regards to differentiation between axial and 
peripheral disease.
Third, misclassification may be an issue, and since PsA classi-
fication criteria are not uniformly registered across the registers, 
case ascertainment was based on the clinical diagnosis entered by 
the treating rheumatologist. When aggregating data from a large 
number of different registers, further difficulties arise regarding 
the operational definitions of exposures and outcomes and in 
assessment of nonrandom missing data. Fourth, of the 13 coun-
tries initially included, only three contributed enough patients to 
be included in all analyses (including secondary analyses). The 
large differences in the number of patients from each register 
will also inevitably lead to an unequal impact on the combined 
results.
Fifth, confounding by indication is likely to affect the results, 
since both the choice of TNFi and the decision to use csDMARD 
comedication may be influenced by factors such as axial versus 
peripheral disease, the extent of cutaneous psoriasis and other 
comorbidities. In this study, we could not precisely identify axial 
disease or other concomitant comorbidities. In the secondary 
analyses, the baseline distributions of swollen joint count and 
DAS28 (online supplemental figure 3) suggested that patients 
with methotrexate comedication had a higher peripheral joint 
disease activity, despite having higher OR of reaching clinical 
remission, thus supporting an effect of comedication.
Finally, changes in csDMARD treatment over the 1- year 
follow- up period were not taken into account, since it was not 
within the aims of the present study to assess csDMARD reten-
tion and since csDMARD data (eg, doses and start/stop dates) 
are poorly captured in the majority of the registers.
Conversely, our study has several strengths. First, it includes a 
large number of patients with PsA with prospectively collected 
data. Second, the possibility of comparing retention and response 
rates across several different registers and to assess heterogeneity, 
adds considerable robustness to the results and their interpreta-
tion. Third, the large number of patients enabled stratification 
of the analysis according to the type of TNFi and methotrexate 
comedication.
In conclusion, we found improved clinical response rates when 
combining TNFi with a csDMARD. More specifically, the rate of 
clinical remission for infliximab and adalimumab increased when 
combined with methotrexate, and the retention of infliximab 
was improved. For etanercept, the remission and retention rates 
did not differ between comedication and monotherapy—and 
were in line with the rates observed for adalimumab comedica-
tion. Our findings support the prevailing strategy, in a situation 
of incomplete response, to continue methotrexate therapy when 
commencing treatment with infliximab or adalimumab, while 
for etanercept methotrexate may be discontinued.
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Supplementary table S1. Description of ethical approvals in the participating countries. 
Country Ethical approval Reference  
Switzerland Local ethical review board approval obtained in Geneva in January 2018. PB_2018-00023-(10-089).  
Czech 
republic 
Ethical approval for ATTRA was granted by the Czech Multicentre Research Ethics Committee. No 
additional ethical approval was required for the current analysis. All subjects provided their 
written consent for the collection and storage of data before participation. 
No. 201611 S300. 
Denmark Not required for registry research Not applicable 
Spain Ethical approval was granted by the Hospital Clínic of Barcelona Ethics Committee (one of the 
participating centers) acting as a reference committee. All patients signed informed consent 
before register inclusion.  
Approval code FER-ADA-2015-01. 
22/May/2015. 
 
Iceland Ethical approval was granted by The National Bioethics Committee and the Icelandic Data 
Protection Authority. 
No Informed Consent is required for registry research. 
Approval number: 18-009 
Ref nr.:VSNb2018010004/03.01 
Italy Ethical approval was granted by the IRB of University Hospital of Bari (the promoting centre) 
acting as a reference committee. All patients signed informed consent before register inclusion. 
Approval number: 598-CE 02/05/2011 
Norway Ethical approvals were granted by the Regional Committees for Medical and Health Research 
Ethics South East. All patients gave their written informed consent. 
Approval numbers: 105-00055, 
2011/1339/REK sør-øst D and 2017/2041 
REK sør-øst A 
Portugal Ethical approval has been granted for the registry and all patients provide informed consent and 
authorize the use of their personal data for investigation, which must be approved by an ethics 
committee (no local approval required). 
Not applicable 
Romania No ethical approval required.  
Sweden Ethical approval granted by the ethical review board in Stockholm. 
No Informed Consent is required for registry research. 
dnr 2015/1844-31/2; 2017/2473-32/1 
Finland Ethical approval granted by the coordinating ethical committee of Helsinki and Uusimaa Hospital 
District 
73/13/03/00/14 
Slovenia Ethical approval granted by the National Medical Ethics Committee at the Ministry of Health of 
the Republic of Slovenia 
0120-191/2016/2 
Turkey The study was approved by both Dokuz Eylul University ethical committee and Turkish Medicines 
and Medical Devices Agency of the Turkish Ministry of Health (#66175679-514.05.01-E.92906). 
Informed consent was obtained from all participants. 
Approval number: 2018/21-02 
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Supplementary table S2. Baseline characteristics (mean (SD) or percentages) of PsA patients starting their first TNFi monotherapy or in combination with a 
csDMARD by country, 2006-2017.  
TNFi in combination with 
csDMARD Switzerland 
Czech 
republic  Denmark Spain Iceland Italy Norway Portugal Romania Sweden Finland Slovenia Turkey 
N (%) 929 (65) 616 (80) 1525 (70) 345 (70) 146 (53) 412 (21) 514 (65) 413 (63) 101 (99) 3574 (65) 493 (78) 252 (72) 120 (57) 
Age, years  49.7 (12.0) 49.1 (11.4) 47.9 (11.7) 49.0 (11.7) 49.9 (13.1) 48.4 (12.3) 47.8 (12.0) 48.8 (11.4) 52.3 (12.0) 49.5 (12.4) 47.8 (11.4) 49.5 (11.3) 43.2 (12.8) 
Sex (male) 48.3% 52.9% 45.2% 49.9% 45.9% 48.8% 50.4% 46.2% 43.6% 51.3% 54.4% 53.6% 35.8% 
Disease duration, years 4.8 (6.1) 8.2 (7.3) 5.7 (6.9) 5.8 (5.5) 7.8 (8.3) 5.6 (6.6) 6.5 (7.6) 6.6 (6.3) 5.2 (7.2) 6.1 (7.4) 8.5 (8.4) 8.4 (7.2) 5.2 (5.3) 
CRP, mg/L   10.1 (15.2) 23.1 (23.1) 12.2 (18.4) 9.2 (15.3) 12.7 (18.6) 3.7 (12.9) 10.4 (16.7) 19.3 (30.6) 36.9 (37.7) 13.4 (37.7) 12.9 (16.6) 16.4 (23.3) 17.9 (22.3) 
Tender joints 28 4.7 (5.3) 10.1 (6.0) 6.5 (6.4) 4.7 (4.6) 5.8 (4.8) 5.5 (6.2) 4.2 (4.7) 7.0 (6.4) 11.9 (7.0) 5.7 (5.5) 3.8 (4.5) 8.6 (5.7) 5.6 (5.4) 
Swollen joints 28 3.3 (4.0) 7.4 (4.9) 2.8 (3.4) 2.9 (3.5) 4.3 (3.4) 2.6 (4.4) 2.2 (3.0) 4.5 (4.2) 7.2 (5.4) 3.7 (4.0) 3.6 (3.7) 7.6 (5.0) 2.4 (2.5) 
VAS global health, mm  51.3 (27.1) 66.7 (21.1) 65.2 (24.3) 59.6 (21.8) 69.4 (22.8) 58.5 (23.2) 50.8 (23.2) 60.8 (23.2) 83.4 (9.9) 56.2 (23.1) 50.4 (25.7) 70.1 (16.8) 61.0 (23.5) 
VAS pain, mm  52.4 (25.8) 62.8 (21.8) 58.4 (23.7) . (.) 64.9 (20.7) 58.9 (24.2) 46.1 (23.9) 60.1 (24.1) - 56.9 (22.6) 53.6 (24.9) 66.4 (24.5) 62.7 (23.9) 
DAPSA28  23.3 (14.6) 41.6 (16.1) 28.5 (15.6) . (.) 31.0 (13.0) 25.8 (18.1) 19.1 (12.0) 32.0 (16.1) - 27.8 (15.1) 25.0 (13.6) 41.3 (17.2) 27.5 (11.9) 
DAS28 -CRP 3.7 (1.2) 5.3 (1.0) 4.2 (1.2) 3.9 (1.0) 4.4 (1.0) 3.6 (1.2) 3.6 (1.1) 4.4 (1.2) 5.8 (1.0) 4.1 (1.1) 3.9 (1.1) 5.0 (1.0) 4.2 (1.0) 
   Adalimumab, % 
40 48 34 34 6 40 15 30 47 27 41 54 42 
   Certolizumab pegol, % 
3 5 9 9 0 1 25 1 0 4 2 4 8 
   Etanercept, % 
25 21 22 32 18 36 31 40 18 37 29 23 26 
   Golimumab, % 
18 12 8 14 14 10 17 19 27 9 9 19 13 
   Infliximab, % 
14 14 29 11 62 14 12 11 9 24 20 1 13 
TNFi Monotherapy              
N (%) 506 (35) 152 (20) 652 (30) 151 (30) 132 (48) 1557 (79) 279 (35) 243 (37) <5 (1) 1888 (35) 140 (22) 99 (28) 92 (43) 
Age, years  47.6 (12.9) 46.3 (11.1) 47.8 (12.7) 49.5 (11.1) 49.2 (12.5) 50.5 (12.2) 47.9 (12.4) 47.8 (11.5) - 49.3 (13.2) 48.4 (11.3) 49.3 (12.3) 41.6 (11.5) 
Sex (male) 54.7% 52% 45.4% 47% 37.1% 46.8% 48.7% 55.6% - 45.4% 55% 52.5% 46.7% 
Disease duration, years 5.1 (7.3) 8.2 (8.1) 5.1 (6.3) 7.0 (7.0) 6.0 (6.3) 6.4 (7.2) 6.6 (8.1) 6.4 (7.4) - 6.3 (8.0) 8.5 (8.3) 5.9 (5.8) 4.9 (5.8) 
CRP, mg/L  10.0 (12.3) 16.2 (19.4) 11.5 (19.8) 3.9 (7.4) 9.3 (10.5) 3.8 (14.2) 10.5 (12.9) 16.4 (22.2) - 11.2 (17.4) 12.4 (24.8) 12.4 (18.2) 16.1 (22.8) 
Tender joints 28 3.7 (5.0) 9.5 (7.0) 7.0 (7.4) 3.3 (4.7) 5.5 (3.9) 5.2 (6.2) 4.4 (5.6) 6.3 (6.2) - 5.6 (5.6) 2.4 (2.9) 7.9 (5.8) 4.3 (4.9) 
Swollen joints 28 2.5 (3.7) 6.7 (5.8) 2.5 (3.4) 2.0 (2.7) 4.2 (3.2) 2.1 (3.8) 1.8 (3.1) 4.3 (4.5) - 3.2 (3.9) 3.8 (5.4) 5.7 (5.3) 2.2 (3.1) 
VAS global health, mm 56.6 (26.3) 68.9 (16.1) 67.3 (23.7) 59.5 (23.3) 68.1 (21.1) 51.8 (28.7) 53.4 (23.3) 61.7 (25.4) - 58.8 (23.0) 46.0 (28.1) 68.9 (17.7) 67.8 (17.1) 
VAS pain, mm 54.6 (25.0) 59.7 (23.7) 59.1 (22.8) . (.) 62.2 (21.2) 51.2 (29.3) 46.7 (23.3) 61.7 (24.0) - 59.4 (22.9) 52.7 (27.8) 64.1 (22.4) 69.8 (18.6) 
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DAPSA28 21.8 (14.3) 39.3 (22.3) 29.2 (17.2) . (.) 30.5 (10.9) 21.7 (17.5) 19.6 (14.6) 31.0 (20.0) - 27.4 (15.3) 22.9 (14.6) 36.6 (18.0) 26.0 (12.3) 
DAS28-CRP 3.6 (1.2) 4.9 (1.2) 4.1 (1.3) 3.2 (1.1) 4.3 (0.9) 3.2 (1.3) 3.6 (1.2) 4.3 (1.5) - 4.0 (1.2) 3.6 (1.1) 4.6 (1.2) 4.0 (1.1) 
   Adalimumab, % 
40 45 44 30 5 35 15 27 - 29 39 53 30 
   Certolizumab pegol, % 
2 5 9 8 1 1 23 1 - 4 3 7 11 
   Etanercept, % 
33 30 28 33 22 46 37 43 - 44 39 19 24 
   Golimumab, % 
14 9 7 16 16 7 18 21 - 9 7 21 21 
   Infliximab, % 
11 11 16 13 56 11 8 9 - 13 12 0 14 
Abbreviations:CRP=C-reactive protein, csDMARD=conventional synthetic disease modifying anti-rheumatic drugs, VAS=visual analogue scale, DAPSA28=disease activity index for psoriatic arthritis with 28 joints, DAS28=disease 
activity score with 28 joints, SD=standard deviation, TNFi=TNF-inhibitors 
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Supplementary table S3. Percentage missing data per country. 
Country Switzerland Czech 
republic 
Denmark Spain Iceland Italy Norway Portugal Romania Sweden Finland Slovenia Turkey All 
Monotherapy baseline missing data 
Age 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Sex 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Disease duration 2 1 14 0 15 32 22 18 0 59 30 1 5 32 
Tender joints 28 53 10 27 44 27 32 7 66 0 29 66 4 32 32 
Swollen joints 28 51 9 27 44 27 32 7 66 0 28 64 4 30 32 
VAS pain, mm 58 49 23 100 36 18 57 74 100 30 50 6 29 34 
VAS global health, mm 59 2 22 46 30 19 8 62 0 29 51 4 29 28 
DAS28-CRP 67 11 34 53 32 40 14 75 0 38 71 4 33 41 
DAPSA28 67 50 34 100 38 40 62 77 100 39 71 10 33 46 
Data on clinical remission 
at 12 month*  
48 11 13 56 22 52 10 35 0 29 55 3 26 35 
Co-medication baseline missing data 
Age 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Sex  0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Disease duration 1 0 10 0 12 25 25 8 0 59 17 0 3 28 
Tender joints 28 42 1 11 34 25 51 7 37 0 17 50 3 33 21 
Swollen joints 28 42 1 12 34 25 51 7 37 0 17 48 3 33 21 
VAS pain, mm 52 40 11 100 26 24 46 48 100 19 33 1 32 30 
VAS global health, mm 53 0 10 37 23 25 4 42 0 18 36 3 32 21 
DAS28-CRP 60 2 16 43 26 60 13 48 0 25 57 3 35 29 
DAPSA28 60 41 17 100 29 60 54 51 100 25 57 4 35 38 
Data on clinical remission 
at 12 months*  
40 8 8 54 10 51 8 20 4 26 51 17 18 25 
Abbreviations: CRP= C-reactive protein, csDMARD= conventional synthetic disease modifying anti-rheumatic drugs, VAS= visual analogue scale, DAPSA28= disease activity index for psoriatic 
arthritis with 28 joints, DAS28= disease activity score with 28 joints, SD= standard deviation, TNFi= TNF-inhibitors. * According to the hierarchal definition outlined in supplementary figure S1. 
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Supplementary table S4. Number of patients included in the country-specific secondary analyses (co-
medication with methotrexate vs monotherapy) stratifying by type of TNFi. 











Country Infliximab Adalimumab Etanercept 
Number of patients included in Cox regression analyses: co-medication/monotherapy 
Czech republic NA* 225/68 87/45 
Finland NA* 146/54 97/55 
Italy 41/169 110/542 106/721 
Portugal NA* 94/66 133/104 
Spain NA* 83/45 81/50 
Slovenia NA* 109/52 NA* 
Iceland 84/74 NA* NA* 
Switzerland 87/56 220/203 142/168 
Sweden 757/243 783/555 1075/836 
Norway NA* 70/41 147/102 
Denmark 357/102 441/289 253/179 
Number of patients included in logistic regression analyses: co-medication/monotherapy 
Pooled 1275/503 1790/1279 1603/1431 
Czech republic NA* 209/63 77/37 
Finland NA* NA* NA* 
Italy NA* 56/260 59/349 
Portugal NA* 78/37 97/68 
Spain NA* NA* NA* 
Slovenia NA* 90/49 NA* 
Iceland NA* NA* NA* 
Switzerland NA* 127/112 82/77 
Sweden 581/176 592/409 762/556 
Norway NA* 63/36 138/92 
Denmark 334/95 396/250 231/154 
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Supplementary figure S3. Baseline distribution of number of tender and swollen joints and DAS28 in 
the secondary analyses. 
 
 
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Ann Rheum Dis
 doi: 10.1136/annrheumdis-2021-220097–9.:10 2021;Ann Rheum Dis, et al. Lindström U
BMJ Publishing Group Limited (BMJ) disclaims all liability and responsibility arising from any reliance
Supplemental material placed on this supplemental material which has been supplied by the author(s) Ann Rheum Dis
 doi: 10.1136/annrheumdis-2021-220097–9.:10 2021;Ann Rheum Dis, et al. Lindström U
Supplementary table S1. Description of ethical approvals in the participating countries. 
Country Ethical approval Reference  
Switzerland Local ethical review board approval obtained in Geneva in January 2018. PB_2018-00023-(10-089).  
Czech 
republic 
Ethical approval for ATTRA was granted by the Czech Multicentre Research Ethics Committee. No 
additional ethical approval was required for the current analysis. All subjects provided their 
written consent for the collection and storage of data before participation. 
No. 201611 S300. 
Denmark Not required for registry research Not applicable 
Spain Ethical approval was granted by the Hospital Clínic of Barcelona Ethics Committee (one of the 
participating centers) acting as a reference committee. All patients signed informed consent 
before register inclusion.  
Approval code FER-ADA-2015-01. 
22/May/2015. 
 
Iceland Ethical approval was granted by The National Bioethics Committee and the Icelandic Data 
Protection Authority. 
No Informed Consent is required for registry research. 
Approval number: 18-009 
Ref nr.:VSNb2018010004/03.01 
Italy Ethical approval was granted by the IRB of University Hospital of Bari (the promoting centre) 
acting as a reference committee. All patients signed informed consent before register inclusion. 
Approval number: 598-CE 02/05/2011 
Norway Ethical approvals were granted by the Regional Committees for Medical and Health Research 
Ethics South East. All patients gave their written informed consent. 
Approval numbers: 105-00055, 
2011/1339/REK sør-øst D and 2017/2041 
REK sør-øst A 
Portugal Ethical approval has been granted for the registry and all patients provide informed consent and 
authorize the use of their personal data for investigation, which must be approved by an ethics 
committee (no local approval required). 
Not applicable 
Romania No ethical approval required.  
Sweden Ethical approval granted by the ethical review board in Stockholm. 
No Informed Consent is required for registry research. 
dnr 2015/1844-31/2; 2017/2473-32/1 
Finland Ethical approval granted by the coordinating ethical committee of Helsinki and Uusimaa Hospital 
District 
73/13/03/00/14 
Slovenia Ethical approval granted by the National Medical Ethics Committee at the Ministry of Health of 
the Republic of Slovenia 
0120-191/2016/2 
Turkey The study was approved by both Dokuz Eylul University ethical committee and Turkish Medicines 
and Medical Devices Agency of the Turkish Ministry of Health (#66175679-514.05.01-E.92906). 
Informed consent was obtained from all participants. 
Approval number: 2018/21-02 
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Supplementary table S2. Baseline characteristics (mean (SD) or percentages) of PsA patients starting their first TNFi monotherapy or in combination with a 
csDMARD by country, 2006-2017.  
TNFi in combination with 
csDMARD Switzerland 
Czech 
republic  Denmark Spain Iceland Italy Norway Portugal Romania Sweden Finland Slovenia Turkey 
N (%) 929 (65) 616 (80) 1525 (70) 345 (70) 146 (53) 412 (21) 514 (65) 413 (63) 101 (99) 3574 (65) 493 (78) 252 (72) 120 (57) 
Age, years  49.7 (12.0) 49.1 (11.4) 47.9 (11.7) 49.0 (11.7) 49.9 (13.1) 48.4 (12.3) 47.8 (12.0) 48.8 (11.4) 52.3 (12.0) 49.5 (12.4) 47.8 (11.4) 49.5 (11.3) 43.2 (12.8) 
Sex (male) 48.3% 52.9% 45.2% 49.9% 45.9% 48.8% 50.4% 46.2% 43.6% 51.3% 54.4% 53.6% 35.8% 
Disease duration, years 4.8 (6.1) 8.2 (7.3) 5.7 (6.9) 5.8 (5.5) 7.8 (8.3) 5.6 (6.6) 6.5 (7.6) 6.6 (6.3) 5.2 (7.2) 6.1 (7.4) 8.5 (8.4) 8.4 (7.2) 5.2 (5.3) 
CRP, mg/L   10.1 (15.2) 23.1 (23.1) 12.2 (18.4) 9.2 (15.3) 12.7 (18.6) 3.7 (12.9) 10.4 (16.7) 19.3 (30.6) 36.9 (37.7) 13.4 (37.7) 12.9 (16.6) 16.4 (23.3) 17.9 (22.3) 
Tender joints 28 4.7 (5.3) 10.1 (6.0) 6.5 (6.4) 4.7 (4.6) 5.8 (4.8) 5.5 (6.2) 4.2 (4.7) 7.0 (6.4) 11.9 (7.0) 5.7 (5.5) 3.8 (4.5) 8.6 (5.7) 5.6 (5.4) 
Swollen joints 28 3.3 (4.0) 7.4 (4.9) 2.8 (3.4) 2.9 (3.5) 4.3 (3.4) 2.6 (4.4) 2.2 (3.0) 4.5 (4.2) 7.2 (5.4) 3.7 (4.0) 3.6 (3.7) 7.6 (5.0) 2.4 (2.5) 
VAS global health, mm  51.3 (27.1) 66.7 (21.1) 65.2 (24.3) 59.6 (21.8) 69.4 (22.8) 58.5 (23.2) 50.8 (23.2) 60.8 (23.2) 83.4 (9.9) 56.2 (23.1) 50.4 (25.7) 70.1 (16.8) 61.0 (23.5) 
VAS pain, mm  52.4 (25.8) 62.8 (21.8) 58.4 (23.7) . (.) 64.9 (20.7) 58.9 (24.2) 46.1 (23.9) 60.1 (24.1) - 56.9 (22.6) 53.6 (24.9) 66.4 (24.5) 62.7 (23.9) 
DAPSA28  23.3 (14.6) 41.6 (16.1) 28.5 (15.6) . (.) 31.0 (13.0) 25.8 (18.1) 19.1 (12.0) 32.0 (16.1) - 27.8 (15.1) 25.0 (13.6) 41.3 (17.2) 27.5 (11.9) 
DAS28 -CRP 3.7 (1.2) 5.3 (1.0) 4.2 (1.2) 3.9 (1.0) 4.4 (1.0) 3.6 (1.2) 3.6 (1.1) 4.4 (1.2) 5.8 (1.0) 4.1 (1.1) 3.9 (1.1) 5.0 (1.0) 4.2 (1.0) 
   Adalimumab, % 
40 48 34 34 6 40 15 30 47 27 41 54 42 
   Certolizumab pegol, % 
3 5 9 9 0 1 25 1 0 4 2 4 8 
   Etanercept, % 
25 21 22 32 18 36 31 40 18 37 29 23 26 
   Golimumab, % 
18 12 8 14 14 10 17 19 27 9 9 19 13 
   Infliximab, % 
14 14 29 11 62 14 12 11 9 24 20 1 13 
TNFi Monotherapy              
N (%) 506 (35) 152 (20) 652 (30) 151 (30) 132 (48) 1557 (79) 279 (35) 243 (37) <5 (1) 1888 (35) 140 (22) 99 (28) 92 (43) 
Age, years  47.6 (12.9) 46.3 (11.1) 47.8 (12.7) 49.5 (11.1) 49.2 (12.5) 50.5 (12.2) 47.9 (12.4) 47.8 (11.5) - 49.3 (13.2) 48.4 (11.3) 49.3 (12.3) 41.6 (11.5) 
Sex (male) 54.7% 52% 45.4% 47% 37.1% 46.8% 48.7% 55.6% - 45.4% 55% 52.5% 46.7% 
Disease duration, years 5.1 (7.3) 8.2 (8.1) 5.1 (6.3) 7.0 (7.0) 6.0 (6.3) 6.4 (7.2) 6.6 (8.1) 6.4 (7.4) - 6.3 (8.0) 8.5 (8.3) 5.9 (5.8) 4.9 (5.8) 
CRP, mg/L  10.0 (12.3) 16.2 (19.4) 11.5 (19.8) 3.9 (7.4) 9.3 (10.5) 3.8 (14.2) 10.5 (12.9) 16.4 (22.2) - 11.2 (17.4) 12.4 (24.8) 12.4 (18.2) 16.1 (22.8) 
Tender joints 28 3.7 (5.0) 9.5 (7.0) 7.0 (7.4) 3.3 (4.7) 5.5 (3.9) 5.2 (6.2) 4.4 (5.6) 6.3 (6.2) - 5.6 (5.6) 2.4 (2.9) 7.9 (5.8) 4.3 (4.9) 
Swollen joints 28 2.5 (3.7) 6.7 (5.8) 2.5 (3.4) 2.0 (2.7) 4.2 (3.2) 2.1 (3.8) 1.8 (3.1) 4.3 (4.5) - 3.2 (3.9) 3.8 (5.4) 5.7 (5.3) 2.2 (3.1) 
VAS global health, mm 56.6 (26.3) 68.9 (16.1) 67.3 (23.7) 59.5 (23.3) 68.1 (21.1) 51.8 (28.7) 53.4 (23.3) 61.7 (25.4) - 58.8 (23.0) 46.0 (28.1) 68.9 (17.7) 67.8 (17.1) 
VAS pain, mm 54.6 (25.0) 59.7 (23.7) 59.1 (22.8) . (.) 62.2 (21.2) 51.2 (29.3) 46.7 (23.3) 61.7 (24.0) - 59.4 (22.9) 52.7 (27.8) 64.1 (22.4) 69.8 (18.6) 
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DAPSA28 21.8 (14.3) 39.3 (22.3) 29.2 (17.2) . (.) 30.5 (10.9) 21.7 (17.5) 19.6 (14.6) 31.0 (20.0) - 27.4 (15.3) 22.9 (14.6) 36.6 (18.0) 26.0 (12.3) 
DAS28-CRP 3.6 (1.2) 4.9 (1.2) 4.1 (1.3) 3.2 (1.1) 4.3 (0.9) 3.2 (1.3) 3.6 (1.2) 4.3 (1.5) - 4.0 (1.2) 3.6 (1.1) 4.6 (1.2) 4.0 (1.1) 
   Adalimumab, % 
40 45 44 30 5 35 15 27 - 29 39 53 30 
   Certolizumab pegol, % 
2 5 9 8 1 1 23 1 - 4 3 7 11 
   Etanercept, % 
33 30 28 33 22 46 37 43 - 44 39 19 24 
   Golimumab, % 
14 9 7 16 16 7 18 21 - 9 7 21 21 
   Infliximab, % 
11 11 16 13 56 11 8 9 - 13 12 0 14 
Abbreviations:CRP=C-reactive protein, csDMARD=conventional synthetic disease modifying anti-rheumatic drugs, VAS=visual analogue scale, DAPSA28=disease activity index for psoriatic arthritis with 28 joints, DAS28=disease 
activity score with 28 joints, SD=standard deviation, TNFi=TNF-inhibitors 
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Supplementary table S3. Percentage missing data per country. 
Country Switzerland Czech 
republic 
Denmark Spain Iceland Italy Norway Portugal Romania Sweden Finland Slovenia Turkey All 
Monotherapy baseline missing data 
Age 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Sex 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Disease duration 2 1 14 0 15 32 22 18 0 59 30 1 5 32 
Tender joints 28 53 10 27 44 27 32 7 66 0 29 66 4 32 32 
Swollen joints 28 51 9 27 44 27 32 7 66 0 28 64 4 30 32 
VAS pain, mm 58 49 23 100 36 18 57 74 100 30 50 6 29 34 
VAS global health, mm 59 2 22 46 30 19 8 62 0 29 51 4 29 28 
DAS28-CRP 67 11 34 53 32 40 14 75 0 38 71 4 33 41 
DAPSA28 67 50 34 100 38 40 62 77 100 39 71 10 33 46 
Data on clinical remission 
at 12 month*  
48 11 13 56 22 52 10 35 0 29 55 3 26 35 
Co-medication baseline missing data 
Age 0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Sex  0 0 0 0 0 0 0 0 0 0 0 0 0 0 
Disease duration 1 0 10 0 12 25 25 8 0 59 17 0 3 28 
Tender joints 28 42 1 11 34 25 51 7 37 0 17 50 3 33 21 
Swollen joints 28 42 1 12 34 25 51 7 37 0 17 48 3 33 21 
VAS pain, mm 52 40 11 100 26 24 46 48 100 19 33 1 32 30 
VAS global health, mm 53 0 10 37 23 25 4 42 0 18 36 3 32 21 
DAS28-CRP 60 2 16 43 26 60 13 48 0 25 57 3 35 29 
DAPSA28 60 41 17 100 29 60 54 51 100 25 57 4 35 38 
Data on clinical remission 
at 12 months*  
40 8 8 54 10 51 8 20 4 26 51 17 18 25 
Abbreviations: CRP= C-reactive protein, csDMARD= conventional synthetic disease modifying anti-rheumatic drugs, VAS= visual analogue scale, DAPSA28= disease activity index for psoriatic 
arthritis with 28 joints, DAS28= disease activity score with 28 joints, SD= standard deviation, TNFi= TNF-inhibitors. * According to the hierarchal definition outlined in supplementary figure S1. 
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Supplementary table S4. Number of patients included in the country-specific secondary analyses (co-
medication with methotrexate vs monotherapy) stratifying by type of TNFi. 











Country Infliximab Adalimumab Etanercept 
Number of patients included in Cox regression analyses: co-medication/monotherapy 
Czech republic NA* 225/68 87/45 
Finland NA* 146/54 97/55 
Italy 41/169 110/542 106/721 
Portugal NA* 94/66 133/104 
Spain NA* 83/45 81/50 
Slovenia NA* 109/52 NA* 
Iceland 84/74 NA* NA* 
Switzerland 87/56 220/203 142/168 
Sweden 757/243 783/555 1075/836 
Norway NA* 70/41 147/102 
Denmark 357/102 441/289 253/179 
Number of patients included in logistic regression analyses: co-medication/monotherapy 
Pooled 1275/503 1790/1279 1603/1431 
Czech republic NA* 209/63 77/37 
Finland NA* NA* NA* 
Italy NA* 56/260 59/349 
Portugal NA* 78/37 97/68 
Spain NA* NA* NA* 
Slovenia NA* 90/49 NA* 
Iceland NA* NA* NA* 
Switzerland NA* 127/112 82/77 
Sweden 581/176 592/409 762/556 
Norway NA* 63/36 138/92 
Denmark 334/95 396/250 231/154 
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Supplementary figure S3. Baseline distribution of number of tender and swollen joints and DAS28 in 
the secondary analyses. 
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